• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

LIPT1 基因表达异常与肝细胞癌脂肪酸代谢失调及预后相关。

Aberrant expression of cuproptosis‑related gene LIPT1 is associated with metabolic dysregulation of fatty acid and prognosis in hepatocellular carcinoma.

机构信息

Department of Histology and Embryology of School of Preclinical Medicine, Guilin Medical University, Guilin, Guangxi, People's Republic of China.

School of Stomatology, Zhaoqing Medical College, Zhaoqing, Guangdong, People's Republic of China.

出版信息

J Cancer Res Clin Oncol. 2023 Nov;149(17):15763-15779. doi: 10.1007/s00432-023-05325-6. Epub 2023 Sep 5.

DOI:10.1007/s00432-023-05325-6
PMID:37668796
Abstract

PURPOSE

Lipoyltransferase 1 (LIPT1) has been recently identified as a cuproptosis‑related gene. As a key enzyme of lipoic acid metabolism, LIPT1 has been revealed to play important roles in hereditary diseases involved with lipoic acid biosynthesis defects, while its roles in hepatocellular carcinoma (HCC) remain to be elucidated. Hence, we aimed to explore the roles and mechanisms of LIPT1 in HCC progression.

METHODS

The expression of LIPT1 in HCC tissues and its clinical significance for HCC were evaluated by bioinformatic analysis and in our patient cohort. The influences of LIPT1 on the growth, migration, and lipid metabolism of HCC cells were assessed in vitro. The underlying mechanisms were explored using gene set enrichment analysis (GSEA) and molecular experiments.

RESULTS

LIPT1 expression was significantly elevated in HCC tissues compared to the normal tissues, and such upregulation was associated with more malignant pathological features and poor prognosis of patients with HCC. LIPT1 silencing significantly inhibited cell proliferation, migration, and lipid content. GSEA revealed that LIPT1 upregulation was significantly associated with various cancer-associated signaling pathways, including the PI3K-AKT signaling pathway and the Wnt/β-catenin pathway. Further molecular experiments indicated that LIPT1 silencing repressed the expression of peroxisome proliferator-activated receptor gamma (PPARγ) and inactivated the AKT/GSK-3β/β-catenin signaling axis.

CONCLUSIONS

Upregulation of LIPT1 is involved in metabolic dysregulation of fatty acid and poor prognosis of HCC patients, which suggests that LIPT1 plays an important role in reprogramming lipid metabolism and could act as a potential prognostic marker and therapeutic target for HCC.

摘要

目的

脂酰基辅酶 A 转移酶 1(LIPT1)最近被鉴定为与细胞铜死亡相关的基因。作为脂酸代谢的关键酶,LIPT1 已被揭示在涉及脂酸生物合成缺陷的遗传性疾病中发挥重要作用,而其在肝细胞癌(HCC)中的作用仍有待阐明。因此,我们旨在探讨 LIPT1 在 HCC 进展中的作用和机制。

方法

通过生物信息学分析和我们的患者队列评估 LIPT1 在 HCC 组织中的表达及其对 HCC 的临床意义。在体外评估 LIPT1 对 HCC 细胞生长、迁移和脂质代谢的影响。使用基因集富集分析(GSEA)和分子实验探讨潜在机制。

结果

与正常组织相比,LIPT1 在 HCC 组织中的表达显著升高,这种上调与更恶性的病理特征和 HCC 患者的不良预后相关。LIPT1 沉默显著抑制细胞增殖、迁移和脂质含量。GSEA 显示,LIPT1 上调与各种癌症相关的信号通路显著相关,包括 PI3K-AKT 信号通路和 Wnt/β-catenin 通路。进一步的分子实验表明,LIPT1 沉默抑制过氧化物酶体增殖物激活受体γ(PPARγ)的表达并使 AKT/GSK-3β/β-catenin 信号轴失活。

结论

LIPT1 的上调参与了脂肪酸的代谢失调和 HCC 患者的不良预后,这表明 LIPT1 在重编程脂质代谢中发挥重要作用,并且可以作为 HCC 的潜在预后标志物和治疗靶点。

相似文献

1
Aberrant expression of cuproptosis‑related gene LIPT1 is associated with metabolic dysregulation of fatty acid and prognosis in hepatocellular carcinoma.LIPT1 基因表达异常与肝细胞癌脂肪酸代谢失调及预后相关。
J Cancer Res Clin Oncol. 2023 Nov;149(17):15763-15779. doi: 10.1007/s00432-023-05325-6. Epub 2023 Sep 5.
2
Prognostic and immunotherapeutic significance of NCAPD2 in pan-cancer and its role in hepatocellular carcinoma progression via the AKT/GSK-3β signaling pathway.NCAPD2在泛癌中的预后及免疫治疗意义及其通过AKT/GSK-3β信号通路在肝细胞癌进展中的作用
Sci Rep. 2025 Jul 1;15(1):21675. doi: 10.1038/s41598-025-96654-8.
3
Upregulated SAE1 Drives Tumorigenesis and Is Associated with Poor Clinical Outcomes in Breast Cancer.SAE1上调驱动肿瘤发生并与乳腺癌不良临床预后相关。
Breast J. 2024 Jun 30;2024:2981722. doi: 10.1155/2024/2981722. eCollection 2024.
4
Transglutaminase 2 Stimulates Cell Proliferation and Modulates Transforming Growth Factor-Beta Signaling Pathway Independently of Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma Cells.转谷氨酰胺酶2刺激肝癌细胞增殖并独立于上皮-间质转化调节转化生长因子-β信号通路。
Int J Mol Sci. 2025 Jun 8;26(12):5497. doi: 10.3390/ijms26125497.
5
SNRPB/CCNB1 axis promotes hepatocellular carcinoma progression and cisplatin resistance through enhancing lipid metabolism reprogramming.SNRPB/CCNB1轴通过增强脂质代谢重编程促进肝细胞癌进展和顺铂耐药。
J Exp Clin Cancer Res. 2025 Jul 18;44(1):211. doi: 10.1186/s13046-025-03463-y.
6
RPL35A Downregulation Suppresses Hepatocellular Carcinoma Cell Proliferation via NCAPG2 Inactivation.RPL35A下调通过NCAPG2失活抑制肝癌细胞增殖。
Cancer Med. 2025 Jun;14(12):e70985. doi: 10.1002/cam4.70985.
7
PLAGL2 as a prognostic biomarker and an EMT-promoting factor in PDAC.PLAGL2作为胰腺癌的一种预后生物标志物和上皮-间质转化促进因子。
Sci Rep. 2025 Jul 14;15(1):25425. doi: 10.1038/s41598-025-09591-x.
8
Integrated network pharmacology and experimental validation reveal EGFR/p53/Bcl-2-mediated anti-hepatocellular carcinoma effects of Zedoary Turmeric Oil.整合网络药理学与实验验证揭示莪术油通过EGFR/p53/Bcl-2介导的抗肝癌作用
J Ethnopharmacol. 2025 Jul 3;352:120241. doi: 10.1016/j.jep.2025.120241.
9
Exploring the mechanism of Naringenin in the treatment of hepatocellular carcinoma based on mRNA sequencing and experimental validation.基于mRNA测序和实验验证探索柚皮素治疗肝细胞癌的机制
Sci Rep. 2025 Jul 2;15(1):23109. doi: 10.1038/s41598-025-09013-y.
10
Integrative analysis reveals that SLC38A1 promotes hepatocellular carcinoma development via PI3K/AKT/mTOR signaling via glutamine mediated energy metabolism.综合分析表明,溶质载体家族38成员1(SLC38A1)通过谷氨酰胺介导的能量代谢,经由磷脂酰肌醇-3-激酶/蛋白激酶B/哺乳动物雷帕霉素靶蛋白(PI3K/AKT/mTOR)信号通路促进肝细胞癌的发展。
J Cancer Res Clin Oncol. 2023 Nov;149(17):15879-15898. doi: 10.1007/s00432-023-05360-3. Epub 2023 Sep 6.

引用本文的文献

1
Targeting cuproptosis in liver cancer: Molecular mechanisms and therapeutic implications.靶向肝癌中的铜死亡:分子机制与治疗意义
Apoptosis. 2025 Aug 7. doi: 10.1007/s10495-025-02150-9.
2
Interaction of ferroptosis and cuproptosis in the perspective of pulmonary hypertension.从肺动脉高压角度看铁死亡与铜死亡的相互作用
Front Cardiovasc Med. 2025 Jun 26;12:1611449. doi: 10.3389/fcvm.2025.1611449. eCollection 2025.
3
Cuproptosis: a novel therapeutic mechanism in lung cancer.铜死亡:肺癌中的一种新型治疗机制。

本文引用的文献

1
Immune checkpoint therapy-current perspectives and future directions.免疫检查点治疗——现状与未来方向。
Cell. 2023 Apr 13;186(8):1652-1669. doi: 10.1016/j.cell.2023.03.006.
2
Tumor microenvironment in ovarian cancer peritoneal metastasis.卵巢癌腹膜转移中的肿瘤微环境
Cancer Cell Int. 2023 Jan 25;23(1):11. doi: 10.1186/s12935-023-02854-5.
3
System analysis based on the cuproptosis-related genes identifies LIPT1 as a novel therapy target for liver hepatocellular carcinoma.基于铜死亡相关基因的系统分析鉴定 LIPT1 为肝癌的一个新治疗靶点。
Cancer Cell Int. 2025 Jun 24;25(1):231. doi: 10.1186/s12935-025-03864-1.
4
Killing hepatocellular carcinoma in the NAFLD/NASH stage: a comprehensive perspective on targeting regulated cell death.在非酒精性脂肪性肝病/非酒精性脂肪性肝炎阶段杀死肝细胞癌:关于靶向程序性细胞死亡的全面观点
Cell Death Discov. 2025 Jun 19;11(1):281. doi: 10.1038/s41420-025-02558-x.
5
Lipoylation inhibition enhances radiation control of lung cancer by suppressing homologous recombination DNA damage repair.脂酰化抑制通过抑制同源重组DNA损伤修复增强肺癌的放射控制。
Sci Adv. 2025 Mar 14;11(11):eadt1241. doi: 10.1126/sciadv.adt1241. Epub 2025 Mar 12.
6
Cuproptosis: molecular mechanisms, cancer prognosis, and therapeutic applications.铜死亡:分子机制、癌症预后及治疗应用
J Transl Med. 2025 Jan 22;23(1):104. doi: 10.1186/s12967-025-06121-1.
7
Copper homeostasis and copper-induced cell death in tumor immunity: implications for therapeutic strategies in cancer immunotherapy.铜稳态与肿瘤免疫中的铜诱导细胞死亡:对癌症免疫治疗策略的启示
Biomark Res. 2024 Oct 31;12(1):130. doi: 10.1186/s40364-024-00677-8.
8
Cuproptosis in cancer: biological implications and therapeutic opportunities.铜死亡在癌症中的作用:生物学意义和治疗机会。
Cell Mol Biol Lett. 2024 Jun 25;29(1):91. doi: 10.1186/s11658-024-00608-3.
9
Cuproptosis Related Gene Associated with Poor Prognosis and Malignant Biological Characteristics in Lung Adenocarcinoma.铜死亡相关基因与肺腺癌预后不良及恶性生物学特征相关
Curr Cancer Drug Targets. 2024;24(8):867-880. doi: 10.2174/0115680096271679231213060750.
J Transl Med. 2022 Oct 4;20(1):452. doi: 10.1186/s12967-022-03630-1.
4
A novel prognostic index of stomach adenocarcinoma based on immunogenomic landscape analysis and immunotherapy options.基于免疫基因组景观分析和免疫治疗选择的胃腺癌新型预后指标。
Exp Mol Pathol. 2022 Oct;128:104832. doi: 10.1016/j.yexmp.2022.104832. Epub 2022 Sep 17.
5
Comprehensive Analysis of Cuproptosis-Related Genes in Immune Infiltration and Prognosis in Melanoma.黑色素瘤中铜死亡相关基因在免疫浸润和预后中的综合分析
Front Pharmacol. 2022 Jun 28;13:930041. doi: 10.3389/fphar.2022.930041. eCollection 2022.
6
Copper induces cell death by targeting lipoylated TCA cycle proteins.铜通过靶向脂酰化 TCA 循环蛋白诱导细胞死亡。
Science. 2022 Mar 18;375(6586):1254-1261. doi: 10.1126/science.abf0529. Epub 2022 Mar 17.
7
The hallmarks of cancer metabolism: Still emerging.癌症代谢的特征:仍在不断涌现。
Cell Metab. 2022 Mar 1;34(3):355-377. doi: 10.1016/j.cmet.2022.01.007. Epub 2022 Feb 4.
8
Predictive biomarkers for systemic therapy of hepatocellular carcinoma.用于肝细胞癌系统治疗的预测性生物标志物。
Expert Rev Mol Diagn. 2021 Nov;21(11):1147-1164. doi: 10.1080/14737159.2021.1987217. Epub 2021 Oct 12.
9
The tumor microenvironment as driver of stemness and therapeutic resistance in breast cancer: New challenges and therapeutic opportunities.肿瘤微环境作为乳腺癌干性和治疗抵抗的驱动因素:新的挑战和治疗机会。
Cell Oncol (Dordr). 2021 Dec;44(6):1209-1229. doi: 10.1007/s13402-021-00634-9. Epub 2021 Sep 16.
10
Identification of Claudin-6 as a Molecular Biomarker in Pan-Cancer Through Multiple Omics Integrative Analysis.通过多组学综合分析鉴定Claudin-6作为泛癌中的分子生物标志物
Front Cell Dev Biol. 2021 Aug 2;9:726656. doi: 10.3389/fcell.2021.726656. eCollection 2021.